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The transplantation of allergens (e.g. Phl p 5 or Bet v 1) expressed on BM cells as
membrane-anchored full-length proteins leads to permanent tolerance at the T-cell,
B-cell, and effector-cell levels. Since the exposure of complete allergens bears the risk
of inducing anaphylaxis, we investigated here whether expression of Phl p 5 in the
cytoplasm (rather than on the cell surface) is sufficient for tolerance induction. Trans-
plantation of BALB/c BM retrovirally transduced to express Phl p 5 in the cytoplasm led
to stable and durable molecular chimerism in syngeneic recipients (∼20% chimerism
at 6 months). Chimeras showed allergen-specific T-cell hyporesponsiveness. Further,
Phl p 5-specific TH1-dependent humoral responses were tolerized in several chimeras.
Surprisingly, Phl p 5-specific IgE and IgG1 levels were significantly reduced but still
detectable in sera of chimeric mice, indicating incomplete B-cell tolerance. No Phl p 5-
specific sIgM developed in cytoplasmic chimeras, which is in marked contrast to mice
transplanted with BM expressing membrane-anchored Phl p 5. Thus, the expression site
of the allergen substantially influences the degree and quality of tolerance achieved with
molecular chimerism in IgE-mediated allergy.
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 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
The induction of tolerance to prevent or treat IgE-mediated aller-
gies is a major goal, since allergic diseases are increasing health
concerns in industrialized nations. Therapeutic induction of tol-
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erance toward allergens can be achieved by allergen-specific
immunotherapy [1, 2]. Subcutaneous injection immunother-
apy applied repeatedly in gradually increasing doses of aller-
gens can alter cellular and humoral allergen-specific immune
responses. The inhibition of allergic inflammation by induction
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of allergen-specific blocking IgG and T-cell tolerance seem to be
mechanisms how subcutaneous injection immunotherapy mod-
ulates the immune system [1–4]. However, allergen-specific
immunotherapy has a number of drawbacks requiring many treat-
ments over a long period of time and pose a significant risk of
severe reactions such as anaphylaxis [5]. Cell-based therapies are
promising strategies to induce tolerance in several immunological
disorders such as autoimmune diseases and organ transplantation
[6–8]. Molecular chimerism is one cell-based therapy approach
based on the transplantation of autologous (i.e. syngeneic in
experimental models) HSCs that have been modified ex vivo to
express disease-causing Ags [9]. The state of co-expression of non-
modified and exogenous Ag-expressing hematopoietic cells (i.e.
molecular chimerism) has been demonstrated to induce robust
and Ag-specific long-term tolerance in some autoimmune disor-
ders and transplantation in preclinical studies [10–12]. Molecular
chimerism studies have been demonstrated to induce T-cell and
B-cell tolerance toward different surface Ags (e.g. membrane-
bound MHC molecules or MOG) and secreted Ags (e.g. proinsulin
II) [13–19].
Recently we showed that expression of major allergens, namely
the grass pollen allergen Phl p 5 (Phleum pratense) and the birch
pollen allergen Bet v 1 (Betula verrucosa), induce robust and
long-lasting tolerance toward the allergen in the peripheral blood
of myeloablatively and nonmyeloablatively conditioned recipi-
ents. Persistent molecular macro- and microchimerism induces
long-term tolerance toward allergens that have been intro-
duced into HSCs as surface proteins [20–22]. In prophylactic
approaches, complete prevention of Phl p 5-specific IgE and IgG
responses could be demonstrated [20]. Besides, T-cell tolerance
and tolerance at the effector-cell level were established in these
studies.
With regard to translating this molecular chimerism strategy to
a therapeutic approach, the surface expression of complete aller-
gens entails the risk of inducing significant side effects (i.e. ana-
phylaxis). The allergenic activity of allergens is mediated by the
number of B-cell epitopes to which IgE can bind and by the num-
ber of T-cell epitopes capable of inducing TH2 responses [23].
Subsequently, the specific recognition of IgE epitopes of the aller-
gen by mast cell bound IgE-antibodies is responsible for devel-
opment of immediate allergic inflammation [1]. The presentation
of complete allergens on the surface of cells could lead to medi-
ator release in presensitized individuals in cell-based approaches
[9]. The use of hypoallergenic allergen derivatives or alternatively
intracellular expression of allergens could potentially avoid this
risk.
Cytosolic proteins are presented via MHC class I to CD8+ T cells
after degradation of the proteins by the proteasome. Such proteins
are additionally presented by MHC class II if they are degraded
through autophagy or TAP-independent pathways [24–27]. It has
been postulated for MHCmolecules that surface expression is nec-
essary to establish central T-cell tolerance [28]. Furthermore, reg-
ulatory T cells were found to be sufficient to control alloantigen-
specific (i.e. T-cell-dependent Ags) B-cell responses by suppressing
T-cell help in a model of heart transplantation using costimu-
lation blockade and donor-specific transfusion [29]. In contrast,
cytosolic expression appears to suffice for non-MHC Ags. [30]. In
a “congeneic” model using cytosolic GFP as the only differing Ag,
chimeric mice became tolerant toward skin grafts (a stringent tol-
erance test in allotransplantation, and did not develop humoral
responses [30, 31]. Thus, T-cell tolerance toward some, but not
all, T-cell-dependent Ags is sufficient to induce B-cell tolerance
when the Ag is expressed in the cytoplasm [29].
Here, we investigated the type and degree of tolerance that can
be achieved by the expression of a clinically relevant respiratory
allergen, Phl p 5, which contains both T- and B-cell epitopes.
Results
Cytoplasmic expression of Phl p 5 in mammalian cells
To introduce the full-length allergen Phl p 5 into the cytoplasm in
HSC, we generated the retroviral vector pMMP-Phl p 5 cyt-eGFP
(Fig. 1A) co-expressing the reporter protein GFP by an internal
ribosomal entry site (IRES). GFP was demonstrated to be non-
toxic when transduced into HSCs [32]. Recombinant retroviruses
were produced in 293 T cells resulting in VSV-Phl p 5-cyt. The
expression of complete Phl p 5 was confirmed in lysates of infected
293 T cells in Phl p 5-specific immunoblot assay (Fig. 1B) show-
ing the same molecular weight like the recombinant (r) Phl p 5.
The membrane-anchored version shows a higher band (due to the
additional transmembrane domain) plus an additional prominent
band possibly due to a posttranslational modification [9]. Further,
Phl p 5 and GFP co-localization in the cytoplasm of mammalian
cells was demonstrated by confocal microscopy of VSV-Phl p 5
cyt transduced murine cells (NIH 3T3 cells; Fig. 1C). Cells trans-
duced with VSV-Phl p 5-cyt did not show expression of Phl p 5
on the surface of 3T3 cells detectable by flow cytometry (FCM),
which is in contrast to 3T3 cells transduced with VSV-Phl p 5-TM
(the membrane-anchored version; Supporting Information Fig.
1). These data demonstrate that transduction with the construct
Phl p 5 allows expression in full length in the cytoplasm. To inves-
tigate whether Ag-presentation of the cytosolic Phl p 5 results
in effective humoral sensitization, mice were subcutaneously
immunized with intact mouse fibroblasts transduced with either
membrane-anchored or cytosolic-expressing Phl p 5. Fibroblasts
expressing Phl p 5 either on the surface or in the cytoplasm induced
specific Ab levels (IgG and IgE; Fig. 1D). Thus, presentation of
the cytoplasmic allergen via MHCII molecules induces allergen-
specific Ab production.
Transplanted VSV-cyt-transduced HSCs induce
long-term molecular macrochimerism
Phl p 5 was integrated into BM cells (BMCs) by retroviral trans-
duction of VSV-Phl p 5-cyt. The transduction efficiency was
determined by FCM (8.2 and 7.1% in two independent
C© 2013 The Authors. European Journal of Immunology published by
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Figure 1. Expression of complete Phl p 5 in the cytoplasmafter transductionwith a retroviral construct. (A) Schematic representation of the plasmid
pMMP-Phl p 5 cyt-eGFP. Long terminal repeats (LTRs) and internal ribosomal entry site (IRES) eGFP expression are indicated. (B) Autoradiography
of an immunoblot showing the specific expression of Phl p 5 in lysates of VSV-Phl p 5-cyt transduced 293 T cells (indicated by an arrow, lane 1),
rPhl p 5 (lanes 2, 4) surface expressed Phl p 5 in lysates of VSV-Phl p 5-TM transduced 293 T cells (lane 3), and rBet v 1 as a negative control (lane 5).
Expression was detected by Phl p 5-specific antibodies. (C) Confocal microscopy of GFP expression in VSV-Phl p 5 cyt transduced cells (left), Phl p 5
was detected exclusively in the cytoplasm of transduced 293 T cells (middle). An overlay of the left and the middle images is shown (right). Images
were taken at 40× magnification. (D) Phl p 5-specific IgE and IgG2a levels in the sera of BALB/c mice (n = 3) immunized with 3T3 cells transduced
with retroviruses to express Phl p 5 on the surface (Phl p 5-TM) or in the cytoplasm (Phl p 5-cyt). Bars represent means. Data shown are from one
experiment representative of two experiments performed.
experiments; Fig. 2A). Further, Phl p 5 and GFP co-expression
in BMCs were confirmed by immunofluorescence (Fig. 2B). Trans-
duced BMCs (7 × 106) were transplanted into preconditioned
BALB/c recipients [20]. GFP expression was determined by FCM
as surrogate marker for Phl p 5 expression in leukocytes of recip-
ients at different time points throughout the follow-up (weeks 4,
7, 11, 17, and 26; Fig. 2C). Stable and persistent macrochimerism
(i.e. chimerism level>1%; n= 16 in two experiments) was evident
C© 2013 The Authors. European Journal of Immunology published by
Wiley-VCH Verlag GmbH & Co. KGaA Weinheim.
www.eji-journal.eu
2454 Ulrike Baranyi et al. Eur. J. Immunol. 2013. 43: 2451–2460
Figure 2. Long-term molecular macrochimerism of Phl p 5-cyt in recipients of VSV-Phl p 5-cyt transduced syngeneic BM. (A) Flow cytometric
analysis of GFP expression in transduced BM cells. Black line histogram represents GFP expression in BM of BALB/c mice transduced with VSV-Phl
p 5-cyt before BMT. Dotted line histogram represents nontransduced BM cells. (B) Expression of GFP (left) by confocal microscopy of transduced
BM cell. Phl p 5 expression was confirmed in the same cells (middle) and an overlay (right). Images were taken at 40× magnification. (C) Expression
of GFP within BM-transplanted recipients. The mean percentage of GFP-expressing CD4+ cells (black diamonds), CD8+ cells (black circles), B220+
cells (open triangles), and myeloid cells (open squares) is shown at several time points until week 28 (n = 10). Data are shown for one of two
representative experiments performed.
in different lineages of white blood cells (monitored through 25
or 28 weeks after BM transplantation (BMT)). Further chimerism
was detectable in spleen, thymus, and BM in FCM at the end of
follow-up (data not shown).
Figure 3. Phl p 5-specific T-cell responses are significantly diminished
in Phl p 5-cyt chimeric mice. Phl p 5-specific T-cell proliferation is
shown in nontransplanted immunizedmice (black circles, n= 6), recipi-
ents of Phl p 5-cyt-transducedBM (black squares, n= 11), andnaı¨vemice
(black triangles, n= 5) stimulatedwith Phl p 5. The ability of splenocytes
to proliferate was confirmed by unspecific stimulation with Con A (data
not shown). Stimulation indices (SI) are shown by Scatter plot (mean
± SD) representing data pooled from two independent experiments.
Statistical significance determined by Man–Whitney U-test.
Phl p 5-cyt molecular chimerism leads to a gross
reduction of T-cell responses
Six, nine, and twelve weeks after BM injection, chimeric mice
were sensitized with rPhl p 5 and, for specificity control with
the major birch pollen allergen rBet v 1. Strong T-cell responses
toward Phl p 5 were measured in splenocyte proliferation assays
in untreated mice after stimulation with rPhl p 5 [20, 33, 34]. In
contrast, chimeric mice showed Phl p 5-specific T-cell unrespon-
siveness (median SI 7 versus 52 for sensitized non-BMT; Fig. 3).
Thus, molecular chimerism with a cytoplasmically expressed aller-
gen induces T-cell hyporesponsiveness.
Phl p 5-specific IgE and IgG1 are diminished
in chimeric mice
To investigate if molecular chimerism expressing Phl p 5 cytoplas-
mically induces tolerance at the B-cell level sera of Phl p 5 chimeric
mice (n = 16) and non-BMT-sensitized mice (n = 10) were ana-
lyzed for Phl p 5-specific IgE levels at several time points through-
out the whole follow-up of 25 or 28 weeks (Fig. 4A). Levels of
Phl p 5-specific IgE were significantly reduced at early time points
(weeks 9 and 12). At later time points, Phl p 5-specific IgE levels in
C© 2013 The Authors. European Journal of Immunology published by
Wiley-VCH Verlag GmbH & Co. KGaA Weinheim.
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Figure 4. Phl p 5-specific IgE and IgG1 is significantly diminished at several time points in Phl p 5-cyt chimeras. (A) The levels of Phl p 5-specific
IgE as determined by ELISA are shown at time points indicated and compared between Phl p 5-cyt chimeric mice (n = 16) and non-BMT-sensitized
mice (n = 10). (B) The levels of Bet v 1-specific IgE are shown as in (A). (C) The levels of Phl p 5-specific IgG1 as determined by ELISA are shown at
time points indicated and compared between Phl p 5-cyt chimeric mice (n = 16) and non-BMT-sensitized mice (n = 10). (D) The levels of Bet v 1-
specific IgG1 are shown as in (C). The Ab levels are depicted as box-and-whisker blots representing the mean, interquartile range (box), and SD
(whiskers) and data shown are from two independent experiments. Statistical significance determined by Man–Whitney U-test.
sera of chimeric mice were diminished numerically but not signif-
icantly compared with those of non-BMT-sensitized control mice.
Levels of IgE of the control allergen Bet v 1 were comparable in
chimeras and non-BMT controls (Fig. 4B). Notably, Phl p 5-specific
IgG1 levels were significantly diminished in sera of chimeric mice
throughout the follow-up of 28 weeks (Fig. 4C). Hence, although
Phl p 5-specific T-cell unresponsiveness was detectable in chimeric
mice expressing Phl p 5 cytoplasmically, and although Phl p 5-IgG1
levels were significantly reduced, Phl p 5-specific IgE showed only
a transient reduction. Thus, TH2-dependent B-cell tolerance was
incomplete.
Low levels of Phl p 5-specific TH1-dependent IgGs
in Phl p 5-cyt chimeric mice
To investigate TH1-related Ab responses, Phl p 5 isotypes IgG2a
and IgG3 were measured (Fig. 5A and B). High levels of Bet v 1-
specific IgG2a and IgG3 were comparable to (Fig. 4 B and D) levels
in sera of control mice (data not shown). Phl p 5-specific IgG2a
and IgG3 were virtually absent even at late time points (28 weeks)
after BMT. Thus, interestingly tolerization mechanisms of TH1-
dependent responses appear to be different from TH2-dependent
humoral responses in this model.
Phl p 5-specific IgM
In previous studies, surface expression of allergens in chimeric
mice led to the complete absence of specific high affinity isotypes
(IgG, IgE, and IgA). However, IgM toward Phl p 5 was detected
in the sera of chimeric mice at late time points despite complete
T-cell tolerance toward Phl p 5 [20]. The production of IgM toward
surface proteins occurs via a T-cell-independent mechanism, while
T-cell help is required for induction of IgG [35]. In a related study,
Bet v 1-specific IgM in sera of chimeras expressing Bet v 1 (instead
of Phl p 5) on the surface of hematopoietic cells was detectable
after BMT even before immunization with rBet v 1. Further, the
C© 2013 The Authors. European Journal of Immunology published by
Wiley-VCH Verlag GmbH & Co. KGaA Weinheim.
www.eji-journal.eu
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Figure 5. Significant reduction of Th1
isotypes and IgM in Phl p 5-cyt chimeric
mice. Phl p 5-specific (A) IgG2a, (B) IgG3,
and (C) IgM levels at late time points of
Phl p 5 chimeric mice (n = 10) and sen-
sitized mice (n = 5) (w28) post-BMT are
shown. (D) Phl p 5-specific IgM levels are
demonstrated in the sera of chimeric
mice expressing membrane-anchored
Phl p 5 (Phl p 5-TM transduced BMT; n =
5), naı¨vemice (n = 5), and chimeric mice
expressing cytoplasmically expressed
Phl p 5 (Phl p 5-cyt-transduced BMT,
n = 16) 6 weeks after BMT. Ab levels
are depicted as box-and-whisker blots
representing mean, interquartile range
(box), and SD (whiskers) and data
shown are pooled from two inde-
pendent experiments. Statistical sig-
nificance determined by Man–Whitney
U-test.
level of IgM did not change even after several immunizations [22].
In the study, herein Phl p 5-specific IgM remained virtually absent
in chimeric mice even at late time points (Fig. 5C). In contrast,
Bet v 1-specific IgM was detectable in all mice (data not shown).
To determine if Phl p 5-specific IgM is T-cell-dependent or T-cell-
independent induced, we compared secreted Phl p 5-specific IgM
in the sera of mice after BMT before immunizations with allergens
6 weeks after BMT (Fig. 5D). None of the mice transplanted with
BM cells that expressed Phl p 5 cytoplasmically — produced IgM
(Fig. 5D) in contrast to sera of mice transplanted with the surface
expressed allergen.
Discussion
The studies presented herein demonstrate that molecular
chimerism with the major grass pollen allergen Phl p 5 expressed
exclusively in the cytoplasm leads to T-cell hyporesponsiveness.
Traditionally, TH2 cells have been defined to produce IL-4,
IL-5, and IL-13 [36]. TH2 cells induce switching of B cells to
IgE and IgG1 in mice. Interestingly, we found that TH2-mediated
humoral responses were reduced but not completely avoided. On
the other hand, TH1-mediated Phl p 5-specific humoral responses
such as IgG2a and IgG3 were virtually absent in most chimeric
mice. Therefore, different mechanisms of tolerance induction such
as suppression by regulatory T cells might be sufficient for TH1 but
not for the TH2-mediated B-cell responses.
In some protocols of molecular chimerism, the level of Ag
expression was described as an important (although controver-
sial) factor for tolerance induction. While low expression levels of
Ag in a molecular chimerism model of hemophilia A led to T-cell
hyporesponsiveness, split tolerance (T-cell versus B-cell tolerance)
was observed toward the secreted Ag [37]. Contrarily, high-level
expression of GFP in syngeneic recipients was described to induce
T-cell tolerance after BMT, nevertheless humoral responses were
C© 2013 The Authors. European Journal of Immunology published by
Wiley-VCH Verlag GmbH & Co. KGaA Weinheim.
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observed. On the other hand, the low-level expression of GFP
showed higher engraftment and no specific Ab responses [38]. In
our study, the chimerism levels were clearly macrochimeric (i.e.
detectable in FCM in different lineages) and quite stable through
the whole follow-up suggesting that the Ag levels are rather high
when mice received BM with allergen expressed cytoplasmically.
Nevertheless, complete B-cell tolerance was achieved when the
allergen was expressed on the surface even when chimerism levels
were microchimeric (chimerism levels not detectable in FCM at
later time points) but persistent [21]. Therefore, the Ag-level
seems not to play a major role for the induction of complete B-cell
tolerance in this model.
In pilot studies of combined kidney and BMT, mixed chimerism
provoked renal allograft acceptance in transplanted individuals
[39]. In most patients, renal allograft tolerance without immuno-
suppression was achieved. Despite T-cell hyporesponsiveness,
B-cell tolerance was not complete as several patients developed
low levels of HLA class II donor-specific antibodies and/or C4d
deposits [40]. Interestingly, these clinical data somewhat resem-
ble with the data in the study herein. Therefore, B-cell toler-
ance needs special attention in the design of chimerism-based
protocols.
Mechanistically, central B-cell tolerance toward surface Ags is
induced in the BM by clonal deletion or receptor editing of auto-
reactive B cells. Moreover, anergy toward soluble self-Ags is pro-
voked in B cells [33,41–44]. Further, B-cell tolerance toward intra-
cellularly expressed Ags was suggested to be maintained by the
absence of T-cell help [45]. Therefore, low T-cell responses might
be responsible for humoral responses toward Phl p 5 expressed
intracellulary as a “self-Ag” in this study. T-cell-independent
Phl p 5-specific IgM production in chimeric mice varied with
the site of Ag expression. While specific IgM was detectable
after exposure of Phl p 5 on the surface, IgM was undetectable
after administration of BM containing cytoplasmically expressed
Phl p 5. Although allergens are T-cell-dependent Ags, some aller-
gens show repeated epitopes and additionally possible posttransla-
tional modifications when expressed in mammalian cells. Possibly,
T-cell-independent IgM might be secreted by B1 cells, a distinct
B-cell population inmice [46]. B cells can act as highly potent APCs
when they endocytose Ags via their specific surface immunoglob-
ulin receptor. While T cells need cell-to-cell contact, B cells are
directly activated through the Ag [47,48].
Therefore, it is likely that in our model B cells are involved
in Ag presentation and that surface exposure of allergens is
indispensable for induction of complete B-cell tolerance. Surface-
expressed allergen peptides or hypoallergenic allergen derivatives
devoid of any IgE cross-linking might be ideal candidates in
this setting to avoid anaphylaxia and to develop more clinically
relevant protocols to avoid IgE-mediated allergy. Although the
safety of cell-based therapeutics and the necessary precon-
ditioning of the recipient are still important limitations, cell
engineering becomes more and more of interest in different fields
of biomedicine and rapid advances in this area might eventually
overcome these hurdles [49].
Overall, these data demonstrate that the site of Ag expres-
sion is an important factor influencing the type and degree of
tolerance achieved by molecular chimerism. Both T-cell and B-cell




Female BALB/c mice were purchased from Charles River Labora-
tories (Sulzfeld, Germany). All mice were housed under specific
pathogen-free conditions and were used between 6 and 12 weeks
of age. All experiments were approved by the local review board
of the Medical University of Vienna, and were performed in accor-
dance with national and international guidelines of laboratory
animal care.
Retroviral construct and production of retroviruses
To generate cytoplasmically expressed Phl p 5, full-length Phl
p 5 was cloned using the optimized mammalian codon usage
(ATG:biosynthetics, Merzhausen, Germany) into the retroviral
vector pMMP-IRES-eGFP via XhoI site resulting in pMMP-Phl
p 5-IRES eGFP. The sequence was confirmed by double-strand
sequencing (VBC-BIOTECH Service GmbH, Vienna, Austria). For
virus production, plasmids pMMP-Phl p 5-IRES eGFP, pMD.G,
encoding for VSV-G protein and pMLV, encoding for viral pro-
teins gag and pol, were cotransfected using the calcium phos-
phate method into 293 T cells [50] resulting in VSV-Phl p 5-cyt
viruses. Viral supernatants were concentrated by ultracentrifuga-
tion (16 500 rpm for 2 h).
BM transduction and BMT
Mice were transduced as described in [20]. Briefly, BALB/c donors
were treated with 5-FU (i.p.) and BMCs isolated cultivated in the
presence of cytokines and transduced with VSV-Phl p 5-cyt with
an multiplicity of infection (MOI) of 5.
Immunization of mice with transduced 3T3 cells
The NIH 3T3 mouse fibroblast cell line was cultivated in the pres-
ence of DMEM (Gibco, Invitrogen, Oregon, USA) media + 10%
FCS and Pen/strep. Cells were transduced with VSV-Phl p 5-TM
and VSV-Phl p 5-cyt with an MOI of 10. High expression levels
were determined in FCM. A total of 2.5 × 106 cells were injected
subcutaneously into na¨ıve BALB/c mice and Phl p 5-specific
Ab levels were determined in ELISAs (e.g. 7 weeks) after
injection.
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Immunoblot
293 T cells were transduced with VSV-Phl p 5-cyt or VSV-Phl p
5-TMD. Lysates of infected cells and rPhl p 5 (Biomay, Vienna,
Austria) were loaded onto a 12% polyacrylamid gel and blotted
to nitrocellulose. A Phl p 5-specific rabbit antiserum was diluted
1:1000 in PBS, 0.05% Tween 20, 2% milk powder. Bound rabbit
antibodies are detected with anti-rabbit HRP-labeled antibodies
diluted 1:2000 in PBS, 0.05% v/v Tween 20, 2%w/vmilk powder.
Reactive bands were visualized with the SuperSignal West Pico
Chemiluminescent Substrate Trial Kit (Pierce, Rockford, IL, USA)
and subsequent exposure to CL-X Posure Film (Pierce).
Immunofluorescence microscopy
Transduced NIH 3T3 cells were grown onto gelatine (1% in PBS)
coated cover slips, transduced BMCs were spun onto glass slides.
Cells were washed twice with PBS, fixed for 10 min with 3%
paraformaldehyde and stained. Cells were permeabilized with
Triton X100 solution and antibodies from a Phl p 5-immunized
rabbit were used with a dilution of 1:200 stained with
fluorochrome-conjugated secondary antibodies (goat α-rabbit IgG
Alexa-Fluor 546 nm, Invitrogen). ProLong Gold antifade reagent
(Molecular probes, Invitrogen) was used. Stained cells were visu-
alized with the confocal laser scanning microscope LSM 510 Meta
(Zeiss, Jena, Germany).
Flow cytometric analysis
To detect transduced cells among various leukocyte lineages,
white blood cells were stained with PE-conjugated antibodies
against CD4, CD8, B220, Mac-1, and isotype controls (Abs from
Biolegend) and analyzed by FCM. Two-color FCM was used to
determine the percentage of GFP-positive cells of particular lin-
eages. The percentage of chimerism was calculated as the net
percentage of GFP-positive cells among leukocyte lineages. 3T3
cells transduced with VSV-Phl p 5-TM or VSV-Phl p 5-cyt were
trypsinized, regenerated for 2 h in DMEM media, and incubated
with Phl p 5-specific rabbit serum (Charles River Laboratories).
Cells were incubated with biotinylated anti-rabbit IgG and stained
with streptavidin-PE (Abs from Biolegend). A Beckman Coulter
flow cytometer (FC500) was used for acquisition, and Beckman
Coulter CXP software (for FC500) was used for analysis of flow
cytometric data.
ELISAs
To measure Ag-specific antibodies in the sera of immunized mice,
ELISAs were performed as described previously [29]. Plates were
coated with the allergens (all obtained from Biomay) rBet v 1 or
rPhl p 5 (5 μg/mL), sera were diluted 1:20 for IgE, 1:100 for
IgM, IgG2a, and IgG3, respectively, and 1:500 for IgG1 and bound
antibodies were detected with monoclonal rat anti-mouse IgM,
IgG1, IgE, IgG2a, and IgG3 antibodies (BD Pharmingen) diluted
1:1000 and a HRP-coupled goat anti-rat antiserum (Biosciences,
UK) diluted 1:2000. The substrate for HRP was ABTS (60 mM/L
citric acid, 77mM/L Na2HPO4 × 2H2O, 1.7mM/L [Sigma-Aldrich,
MO, USA], 3 mM/L H2O2).
Lymphocyte proliferation assay
Spleens were removed under aseptic conditions and homogenized.
Single-cell suspensions were filtered through a 70 μm nylon cell
strainer to remove remaining tissue. Erythrocytes were removed
by adding cold lysing buffer (Red Blood Cell Lysing Buffer, Sigma-
Aldrich). Cells were diluted to a final concentration of 2 ×
106 cells/mL and triplicates of 100 μL/well were sowed in 96-well
round-bottom plates. Stimulants were added at a concentration of
2 μg/well allergen or as control for proliferation, 0.5 μg/well
Con A (Sigma-Aldrich). The plates were incubated at 37◦C, 5%
CO2. On day 4, 0.5 μCi H3 thymidine ([methyl-3H], Amersham)
per well was added. Sixteen hours later, cells were harvested and
thymidine uptake measured in a beta counter (Beta scintillation
liquid, Wallac).
Statistical analysis
The reported p-values are results of the Mann–Whitney U-test.
p-Values < 0.05 were considered statistically significant. Error
bars indicate SDs. Graph pad prism statistical software (version
5.01) was used for statistical calculations.
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